Red Blood Cell Transfusion

Oral vadadustat three times per week was noninferior to a long-acting erythropoiesis-stimulating agent for treating anemia in patients with chronic kidney disease on dialysis, according to study data.

An FDA advisory committee voted 12-2 that the benefits of the investigational therapy imetelstat outweigh the risks for the treatment of transfusion-dependent anemia in certain adults with myelodysplastic syndromes.

The FDA approved sutimlimab-jome infusion for the treatment of adults with a rare type of anemia.

Higher red blood cell transfusion rates correlated with higher odds for morbidity and mortality among patients who underwent elective GI cancer resection, according to a presentation at Digestive Disease Week.

The American College of Gastroenterology published clinical guidelines regarding the management of patients with overt upper gastrointestinal bleeding.

Treatment with imetelstat led to durable transfusion independence for certain heavily transfused patients with lower-risk myelodysplastic syndrome, according to study results published in Journal of Clinical Oncology.